These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11857006)

  • 1. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
    van der Burg ME; de Wit R; van Putten WL; Logmans A; Kruit WH; Stoter G; Verweij J
    Br J Cancer; 2002 Jan; 86(1):19-25. PubMed ID: 11857006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
    de Wit R; van der Burg ME; van den Gaast A; Logmans A; Stoter G; Verweij J
    Ann Oncol; 1994 Sep; 5(7):656-7. PubMed ID: 7993845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
    Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ
    Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
    Verborg WA; Campbell LR; Highley MS; Rankin EM
    Int J Gynecol Cancer; 2008; 18(2):228-34. PubMed ID: 17511798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
    Morgan RD; Clamp AR; Hasan J; Mitchell C; Saunders G; Mescallado N; Welch R; Jayson GC
    Int J Gynecol Cancer; 2018 Mar; 28(3):448-452. PubMed ID: 29466253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
    Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the role of dose-dense therapy?
    van der Burg ME; van der Gaast A; Vergote I; Burger CW; van Doorn HC; de Wit R; Stoter G; Verweij J
    Int J Gynecol Cancer; 2005; 15 Suppl 3():233-40. PubMed ID: 16343238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide.
    Zanaboni F; Scarfone G; Presti M; Maggi R; Borello C; Bolis G
    Gynecol Oncol; 1991 Oct; 43(1):24-8. PubMed ID: 1959783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
    van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
    Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1995 Jul; 6(6):613-5. PubMed ID: 8573543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
    Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
    Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
    Baur M; Schernhammer E; Gneist M; Sevelda P; Speiser P; Hudec M; Dittrich Ch
    Br J Cancer; 2005 Mar; 92(6):1019-25. PubMed ID: 15756278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma.
    Stuart K; Posner M; Campbell K; Huberman M
    Am J Clin Oncol; 1995 Aug; 18(4):300-2. PubMed ID: 7625370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
    van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
    Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
    Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
    Aravantinos G; Dimopoulos MA; Kosmidis P; Bafaloukos D; Papadimitriou C; Kiamouris C; Pavlidis N; Sikiotis K; Papakostas P; Skarlos DV
    Ann Oncol; 2000 May; 11(5):607-12. PubMed ID: 10907957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.